View Item 

Show simple item record

Detección, valoración y tratamiento de la hipercolesterolemia en adultos

dc.contributor.authorAnones_ES
dc.date.accessioned2015-08-25T14:52:02Z
dc.date.available2015-08-25T14:52:02Z
dc.date.issued2001es_ES
dc.identifier.citationAnon (2001) Detección, valoración y tratamiento de la hipercolesterolemia en adultos. Rev Panam Salud Publica;9(5) 328-344,mayo 2001. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500019&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500019&lng=pt&nrm=iso&tlng=eses_ES
dc.identifier.urihttps://iris.paho.org/handle/10665.2/7835
dc.format.extenttabes_ES
dc.relation.ispartofseriesRev Panam Salud Publica;9(5),mayo 2001es_ES
dc.subjectHipercolesterolemiaes_ES
dc.subjectSíndrome metabólicoes_ES
dc.subjectFactores de Riesgoes_ES
dc.subjectPrevención y Mitigaciónes_ES
dc.subjectFarmacoterapiaes_ES
dc.titleDetección, valoración y tratamiento de la hipercolesterolemia en adultoses_ES
dc.title.alternativeDetection, evaluation, and treatment of high blood cholesterol in adultsen_US
dc.typeJournal articlesen_US
dc.rights.holderPan American Health Organizationen_US
dc.description.notesThis report is based on the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, which was recently issued by the National Institutes of Health of the United States of America. Also known as the Adult Treatment Panel (ATP) III, this new report updates two earlier such reports on high cholesterol. While continuing to concentrate on treating patients with coronary heart disease, the new report advocates more intensive treatment in order to reduce low-density lipoprotein (LDL) cholesterol in specific groups of individuals, pays special attention to primary prevention among patients with multiple risk factors, and recognizes as a secondary prevention concern a cluster of heart disease risk factors known as "the metabolic syndrome." Other issues that the ATP III report covers include therapeutic lifestyle changes to reduce LDL, LDL-lowering drug therapy, and the management of specific dyslipidemias.(AU)en_US


Files in this item

Thumbnail
Name:
5138.pdf
Size:
70.22Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record